TruGraf Liver Logo

The first and only Non-Invasive Blood-Based RNA Gene Expression diagnostic test that provides guidance for controlled reduction of immunosuppression, by confirming immune quiescence for rejection in post therapy adjustment for Liver Transplant recipients

TruGraf® Liver Confirms Immune Quiescence and Offers Biomarker Guidance for Immunosuppression

Liver transplant recipients feel the burden of immunosuppression.

27%

of LTRs with grafts >1 year die of malignancy or infection 1

12%

experience liver rejection in the first year 2

20%

experience chronic renal failure in the first 5 years of graft life 1

40%

develop post-transplant diabetes mellitus 1

45%

develop dyslipidemia 1

How do you ensure patients receive optimal immunosuppressant therapy?

 

A New Way to Optimize Immunosuppression

Introducing TruGraf® Liver, the first and only Non-Invasive Blood-Based RNA Gene Expression diagnostic test that provides guidance for controlled reduction of immunosuppression, by confirming immune quiescence for rejection in post therapy adjustment for Liver Transplant recipients

 

Biomarkers provide critical information that help guide clinical decision making and personalize patient care.

 

TruGraf Liver Logo

 

83% NPV

Negative Predictive Value

43% PPV

Positive Predictive Value

References:

  1. Tasdogan BE, et al. EJOHG 2019; 9 (2): 96–101.
  2. Kwong AJ et al. Am J Transpl 2022; 22 (S2): 204–309.